000 | 01931 a2200553 4500 | ||
---|---|---|---|
005 | 20250514071529.0 | ||
264 | 0 | _c20030807 | |
008 | 200308s 0 0 eng d | ||
022 | _a0278-0232 | ||
024 | 7 |
_a10.1002/hon.705 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSato, Naoko | |
245 | 0 | 0 |
_aThe effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. _h[electronic resource] |
260 |
_bHematological oncology _cJun 2003 |
||
300 |
_a67-75 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAntigen Presentation _xdrug effects |
650 | 0 | 4 |
_aAntigens, CD _xmetabolism |
650 | 0 | 4 | _aBenzamides |
650 | 0 | 4 | _aCells, Cultured |
650 | 0 | 4 |
_aChromosomes, Human, Pair 22 _xgenetics |
650 | 0 | 4 |
_aChromosomes, Human, Pair 9 _xgenetics |
650 | 0 | 4 | _aDNA Probes |
650 | 0 | 4 |
_aDendritic Cells _ximmunology |
650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
650 | 0 | 4 | _aFlow Cytometry |
650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xmetabolism |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImatinib Mesylate |
650 | 0 | 4 | _aIn Situ Hybridization |
650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
650 | 0 | 4 |
_aLeukocytes _xdrug effects |
650 | 0 | 4 |
_aPiperazines _xpharmacology |
650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
650 | 0 | 4 |
_aPyrimidines _xpharmacology |
650 | 0 | 4 | _aTranslocation, Genetic |
700 | 1 | _aNarita, Miwako | |
700 | 1 | _aTakahashi, Masuhiro | |
700 | 1 | _aYagisawa, Kumiko | |
700 | 1 | _aLiu, Aichun | |
700 | 1 | _aAbe, Takashi | |
700 | 1 | _aNikkuni, Kohji | |
700 | 1 | _aFurukawa, Tatsuo | |
700 | 1 | _aToba, Ken | |
700 | 1 | _aAizawa, Yoshifusa | |
773 | 0 |
_tHematological oncology _gvol. 21 _gno. 2 _gp. 67-75 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1002/hon.705 _zAvailable from publisher's website |
999 |
_c12587212 _d12587212 |